Background: Evidence from clinical studies and preclinical animal models suggests that proinflammatory cytokine overproduction is a potential driving force for pathology progression in traumatic brain injury (TBI). This raises the possibility that selective targeting of the overactive cytokine response, a component of the neuroinflammation that contributes to neuronal dysfunction, may be a useful therapeutic approach. MW151 is a CNS-penetrant, small molecule experimental therapeutic that selectively restores injury-or disease-induced overproduction of proinflammatory cytokines towards homeostasis. We previously reported that MW151 administered post-injury (p.i.) is efficacious in a closed head injury (CHI) model of diffuse TBI in mice. Here we test dose dependence of MW151 to suppress the target mechanism (proinflammatory cytokine up-regulation), and explore the therapeutic window for MW151 efficacy.
Introduction
Traumatic brain injury (TBI) is a public health problem associated with injuries sustained by military personnel, concussion-related sports injuries, and falls in the elderly [1] . TBI initiates a cascade of complex pathophysiological events that can themselves add to physiological injury and the longer-term morbidity related to neurodegenerative complications. For example, TBI increases susceptibility for development of Alzheimer's disease (AD) and other dementias, post-traumatic epilepsy, neuropsychiatric disorders, post-traumatic stress disorder, and chronic traumatic encephalopathy. The diverse neurologic sequelae of TBI can occur months, years, even decades after the last head injury [2] [3] [4] . Thus, it is critical to elucidate the underlying pathophysiology by which an initial TBI elicits an enhanced susceptibility to subsequent injuries and neurologic complications.
A key mechanism that drives pathophysiology progression in many CNS disorders involves abnormal inflammatory responses in the brain, termed neuroinflammation (for recent reviews, see [5, 6] ). Studies with animal models and human head injury patients suggest that proinflammatory cytokine overproduction is one component of the neuroinflammation that contributes to adverse outcomes following TBI [7, 8] . This raises the importance of exploring attenuation of proinflammatory cytokine overproduction as a therapeutic target.
We developed [9] a CNS-penetrant, small molecule experimental therapeutic, MW01-2-151WH (MW151), that selectively restores injury-or disease-induced overproduction of proinflammatory cytokines towards homeostasis. MW151 is efficacious in a variety of animal models of diseases where proinflammatory cytokine overproduction is a component of disease progression, including (1) animal models of Alzheimer's disease [9, 10] ; (2) neurologic sequelae of seizures [11, 12] ; (3) EAE model of multiple sclerosis [13] ; (4) a 'two-hit' injury model of increased susceptibility to seizures after a TBI [14] , and (5) radiation-induced cognitive impairment [15] . Particularly relevant to the current study, we have previously reported [16] that MW151 is efficacious in a closed head injury (CHI) model of diffuse TBI in mice, when administered during the time of the acute post-injury cytokine surge. The observation that MW151 attenuates disease-and injury-induced proinflammatory cytokine overproduction and reduces downstream synaptic and cognitive dysfunction in multiple animal models of CNS disorders suggests that further development of MW151 is warranted.
A key component of developing proinflammatory cytokine modulators for altering disease progression is consideration of dosing. Dosing is the pharmacological basis of therapeutic action and includes the amount of drug administered, the frequency of administration, and the time window during disease progression for administration. The goal of this study was to probe the time window and concentration dependence of MW151 intervention to suppress the targeted mechanism, proinflammatory cytokine upregulation, and the impact of appropriate dosing on efficacy and attenuation of downstream cognitive dysfunction.
Materials and methods

Animals
The Institutional Animal Care and Use Committee of the University of Kentucky approved the use of animals in this study, which were conducted in accordance with the principles of animal care and experimentation in the Guide for the Care and Use of Laboratory Animals. All experiments used adult male C57BL/6 J mice obtained from Jackson Laboratory. Animal experiments followed the recent NIH guidelines for rigor in study design and analysis [17, 18] , including randomization of animals and blinding of treatment groups and tissue samples.
Surgical procedure
Adult mice were subjected to a CHI using a stereotaxic electromagnetic impactor [19] . Under continuous inhalation of isoflurane (3.5%, 1 liter/min) anesthesia, with the head stabilized using ear bars in a digital mouse stereotaxic frame (Stoelting Co., Wood Dale, USA), a midline sagittal scalp incision was made. To displace the force of the impact, a 1-ml latex pipette bulb (ThermoFisher Scientific, Waltham, USA) was placed under the head and filled with water. A 5.0-mm steel tip impounder (Leica Biosytems, Wetzlar, Germany) was used to deliver a single controlled midline cortical impact, delivered at coordinates: ML = 0.0 mm; AP = −1.5 mm, with a controlled velocity (5.0 ± 0.2 m/s), dwell time (100 ms), and impact depth (1.0 mm). Mice with depressed skull fracture or visible hemorrhage were excluded from the study. Shaminjured mice underwent identical surgical procedures as the trauma group, but no impact was delivered. The time elapsed until the animal spontaneously rights was recorded as an acute neurological assessment, and defined as the righting reflex time. In this mild diffuse injury model, the mortality rate is <1%. Following each surgery, animals were monitored continuously until they have fully recovered.
Synthesis and use of MW151
MW01-2-151SRM (2-(4-(4-methyl-6-phenylpyridazin-3-yl)piperazin-1-yl)pyrimidine) was synthesized and characterized as previously reported [9] . As previously described [10] , MW151 was dissolved in 0.9% sterile NaCl (saline: Hospira NDC 0409-4888-10), and administered by intraperitoneal (i.p.) injection. Saline was injected i.p. as the vehicle control.
Radial arm water maze behavior
A 2-day radial arm water maze (RAWM) protocol was used as previously described [20] . Briefly, in block 1 (first 6 trials) and block 2 (6 trials), mice were trained to identify the platform location by alternating between a visible and a hidden platform (3 hidden platform trials and 3 visible platform trials for each block). Block 3 (3 trials) used only a hidden platform. The next day, mice were tested in 3 blocks of 5 trials each (blocks 4 to 6; 15 total trials), all using only a hidden platform to test their spatial memory retention. EthoVision XT 8.0 video tracking software (Noldus Information Technology, Wageningen, The Netherlands) was used to record and score the behavior. Data are presented as the average errors per block during the hidden platform trials.
Brain tissue harvesting, biochemical, and immunohistochemical endpoints
Mice were deeply anesthetized with 5% isoflurane prior to transcardial perfusion with ice-cold PBS for 5 min, then the brains were rapidly removed and dissected, as previously described [10, 21] . Cytokine and chemokine levels were measured in brain homogenates using Meso Scale Discovery (MSD) ELISA, as previously described [10, 21] . Immunohistochemical (IHC) staining was done following established methods, and quantified using the Aperio ScanScope XT digital slidescanner and Aperio ImageScope software positive pixel count algorithm (version 9), as previously described [10, 21] . Primary antibodies used included rabbit anti-glial fibrillary acidic protein (GFAP) (Dako Cat#Z0334; (1:10,000); Dako, Glostrup, Denmark); rabbit anti-IBA1 (Wako Cat#019-19741; (1:10,000); Wako Chemicals USA Inc., Richmond, USA); and rat anti-CD45 (YW62.3) (ThermoFisher Scientific Cat#MA1447081; (1:10,000); ThermoFisher Scientific, Waltham, USA).
Statistics
JMP software version 10.0 was used for statistical analysis. A repeated measures ANOVA was used for RAWM. For all other endpoints, a one-way ANOVA was used to examine differences within those factors. A two-tailed Student's t test was used for post hoc analysis to compare only the effect of injury compared to sham and to compare the effect of MW151 compared to vehicle in the injured mice, as these comparisons were determined a priori to be the ones of interest. Differences between means were considered significant at α = 0.05. Graphs were generated using GraphPad Prism software version 6.0, and values are expressed as mean ± SEM, unless otherwise noted.
Results and discussion
Selection of preclinical model and validation of mechanism of action
In the field of neurotrauma, a number of preclinical models have been characterized (for review of rodent TBI protocols, see [22] ). Because no single animal model can reproduce the complexity of TBI pathology seen in humans, it is important to choose a model that has an injury with some relevance to the clinical paradigm. Most important for pharmacological studies, the model should exhibit changes in the targeted pathways in order to test mechanistic pharmacodynamics, or how drug intervention alters the mechanism of action. For this study, we chose a midline CHI protocol that uses an electromagnetic impactor and produces a diffuse brain injury without focal brain lesions, fracture of the skull, or hemorrhages. Mild diffuse injury after closed-skull impact is similar to the injury characteristics observed most commonly in human head injury. In addition, this experimental protocol produces a reproducible injury with low mortality, making it technically feasible for pharmacological studies.
MW151 was developed [9] using the classic functional approach with the focus on a deliverable with the following desired pharmacological properties: selective suppression of stressor-induced up-regulation of neuroinflammatory responses of activated glia such as proinflammatory cytokine overproduction. An advantage of the functional approach is the unbiased focus on attenuation of pathology progression, with potential for identification of alternative therapeutic strategies, which has resulted in historical success in delivering widely used drugs to clinical practice. Our discovery process to develop novel small molecules began with a validated mouse model [23] [24] [25] and discovery engine that used novel molecule design based on pharmacoinformatics and a curated database of CNS-penetrant drugs. The starting point for the family of compounds encompassing MW151 and its analogs was a chemical scaffold present in previous clinically useful CNS drugs. The strict exclusion criteria of the approach resulted in the synthesis and testing of fewer than two dozen novel small molecules to find viable hits. Focused medicinal chemistry refinement was then done to improve metabolic stability and pharmacokinetic features. MW151 was one of two best-in-class deliverables from the discovery engine's hierarchal pharmacological screening process.
MW151 is a water-soluble, chemically stable, small molecule (423 MW) that is orally bioavailable and CNSpenetrant, with a brain:blood ratio >1, similar to other CNS drugs in clinical use or under development. MW151 is selective in its action and is not a pansuppressor of neuroinflammation. For example, MW151 suppresses disease-and injury-induced overproduction of proinflammatory cytokines such as IL-1β and TNFα, but does not block anti-inflammatory cytokines such as IL-10 [10]. MW151's pharmacological mechanism of action is one that restores activated pathways back towards homeostasis, as shown by its lack of effect in control animals and its failure to depress basal cytokine levels at efficacious doses. Further, efficacy is achieved in the absence of any signs of general immunosuppression or non-selective anti-inflammatory action [9] [10] [11] [12] [13] [14] [15] [16] 26] . Therefore, future development of MW151 could have broad clinical applications for a number of other CNS disorders where proinflammatory cytokine dysregulation is part of the pathophysiology progression mechanism and restoration towards homeostasis is the desired therapeutic goal.
A critical first step before testing MW151 in the CHI model was to validate that the model exhibits an injury-induced acute proinflammatory cytokine surge, the mechanism of action targeted by MW151. Therefore, we subjected mice to CHI and measured IL-1β levels in the cortex at various post-injury (p.i.) time points. As shown in Figure 1A , levels of IL-1β in the cortex began to rise at 3 h p.i., peaked at 9 h p.i., and returned to pre-injury levels by 12 to 24 h p.i. This pattern of the acute cytokine surge is similar to that found previously in a comparable CHI model [16] , although that CHI protocol resulted in a slightly delayed peak IL-1β level (12 h). The reason for the slight temporal difference in IL-1β response is unknown, but could reflect strain differences in the mice (C57BL/6 J vs. CD-1), or minor variations in the CHI models. Previously, Lloyd et al. showed that administration of MW151 (5 mg/kg i.p.) at two post-injury time points when cytokines were increasing (3 h and 9 h) significantly reduced the peak (12 h p.i.) of the proinflammatory cytokine (that is, IL-1β) surge in the CNS [16] . To confirm that MW151 administration in our midline CHI model would suppress IL-1β, we injected MW151 (5 mg/kg i.p.) at two time points (3 h and 6 h) during the acute rise in IL-1β, and harvested brain tissue at the 9-h p.i. peak IL-1β time point. As shown in Figure 1B , MW151 administered under this treatment paradigm significantly reduced the IL-1β levels in the cortex at 9 h p.i., demonstrating engagement of the pharmacological mechanism of action by MW151.
Intervention time window for suppression of acute cytokine surge by MW151
After confirming that our CHI model showed the predicted acute cytokine surge and that two administrations of MW151 suppressed this surge, we tested whether a single injection of MW151 administered at different times after injury would be effective at inhibiting IL-1β levels. We tested intervention at two clinically relevant time windows, 3 h or 6 h following CHI. MW151 (5 mg/kg i.p.) was injected at either 3 or 6 h p.i., brain harvested at the 9-h p.i. time point, and IL-1β levels in cortex homogenates determined. A positive control group that received two injections of MW151 (at 3 and 6 h p.i.) was also included. In the vehicle-treated groups (sham or CHI), there was no difference in IL-1β levels in the groups treated at 3, 6, or 3 and 6 h p.i.; therefore, these vehicle treatment groups were Table 1 ). Strikingly, we found that MW151 (5 mg/kg) significantly reduced IL-1β levels almost to preinjury levels, not only when two injections were given (3 and 6 h), but even after a single administration at either 3 or 6 h p.i. (58%, 63%, and 61% decrease from CHI + veh, respectively) ( Figure 1C ). MW151 administration also reduced IL-6 levels ( Figure 1D ), but the decrease did not reach statistical significance. In addition, we found that MW151 did not significantly reduce the levels of the antiinflammatory cytokine IL-10, or the chemokines CCL2 or CXCL1 ( Figure 1D ). The lack of effect of MW151 on CCL2 levels in our CHI model is in contrast to previous findings [16] in a different CHI model, but the reason for this difference was not explored further. Our data with acute administration of MW151 demonstrate that the injury-induced IL-1β levels are inhibited even when MW151 is administered at 6 h p.i. and that the compound shows selectivity for IL-1β and IL-6 compared to the other markers measured.
Concentration dependence of MW151 inhibition of post-injury IL-1β up-regulation
To determine whether MW151 showed dose-dependent suppression of IL-1β in the CNS following a CHI, we tested three different doses of MW151 (1, 5, and 10 mg/kg) administered at a single time (6 h p.i.). Brain tissue was harvested at 9 h p.i., and levels of IL-1β and CCL2 in the cortex were measured, to assess the target mechanism of inhibiting proinflammatory cytokine overproduction (IL-1β) and to assess the selectivity of MW151 by determining if it would suppress CCL2 levels at higher doses. As shown in Figure 2 , MW151 showed dose-dependent suppression of IL-1β up-regulation, with significant inhibition at doses of 5 and 10 mg/kg. MW151 had no effect on injuryinduced CCL2 levels at any dose tested.
Functional efficacy of MW151 to suppress CHI-induced cognitive impairment
We tested the potential of MW151 to suppress injuryinduced cognitive deficits in two different treatment paradigms ( Figure 3A) . In the first paradigm, MW151 (5 mg/kg) was administered at 3 and 6 h p.i., and then once daily for 7 days. This extended treatment approach uses a similar dosing paradigm to a previous report showing that a structural analog of MW151 can rescue TBI-induced cognitive impairments [27] . In the second paradigm, a single dose of MW151 (5 mg/kg) was given at the 6-h p.i. time point. In both treatment paradigms, mice were tested starting at day 14 p.i. for cognitive impairment in the RAWM. The rationale for this experimental design was to test if suppression of the peak IL-1β response with CHI + MW151 at 3 h and 6 h (n = 10) 7.0 ± 3.8 22.0 ± 13.7 6.5 ± 3.0 403.3 ± 134.5 235.6 ± 125.9
CHI + MW151 at 3 h (n = 10) 6.8 ± 2.5 21.4 ± 15.4 5.6 ± 4.6 393.5 ± 134.6 214.6 ± 132.1
CHI + MW151 at 6 h (n = 9) 6.8 ± 2.5 23.7 ± 21.7 6.9 ± 4.3 414.2 ± 134.5 246.9 ± 88.3
Data are expressed as pg/ml/mg (mean ± SD). CHI, closed head injury; veh, vehicle.
Figure 2 Dose-dependent suppression of IL-1β up-regulation by MW151. Mice were subjected to sham injury or CHI, and injected i.p. at 6 h p.i. with saline vehicle (veh). CHI mice were injected i.p. at 6 h p.i. with MW151 at one of three different doses (1, 5, and 10 mg/kg). Levels of IL-1β (A) and CCL2 (B) protein were measured in cortex homogenates at the 9-h p.i. time point. *P < 0.05, ***P < 0.001 compared to sham mice. ‡P < 0.05, ‡ ‡P < 0.01 CHI + veh compared to CHI + MW151 (n = 10 sham + veh; n = 20 CHI + veh; n = 9 to 10 CHI + MW151).
a single administration of MW151 given at 6 h p.i. would be sufficient to prevent subsequent cognitive impairment assessed 2 weeks later or if a more extended treatment was required. As shown in Figure 3B , the CHI mice treated with vehicle showed a significant impairment in RAWM compared to the sham group. MW151 administered under the extended treatment paradigm (3 h, 6 h, and 1 to 7 days p.i.) led to a significant improvement in RAWM performance. However, a single injection of MW151 at 6 h p.i. did not reduce the CHI-induced cognitive impairment in the RAWM assessed 2 weeks later. There are several possible interpretations of these results. It is possible that a single 6-h p.i. administration of MW151, Figure 3 Functional efficacy of MW151 to suppress CHI-induced cognitive impairment. (A) Overview of study design. MW151 (5 mg/kg i.p.) was administered either as a single acute treatment at 6 h p.i. or in a more extended treatment paradigm (3 h, 6 h, then once daily for 7 days p.i.). (B) Mice were tested for cognitive deficits in the RAWM starting at 14 days p.i. (n = 23 sham; n = 27 CHI + veh; n = 12 CHI + MW150 acute; n = 14 CHI + MW150 chronic).
while effective at suppressing the peak of the IL-1β response, may be too late to inhibit other key proinflammatory cytokines that show an earlier post-injury surge and that may contribute to subsequent impairment. It is also possible that other detrimental neuroinflammatory responses that contribute to cognitive impairment occur during the first 7 days p.i. and that administration of MW151 during this time window inhibits those responses. Finally, it is possible that a single administration of MW151 is not sufficient to prevent cognitive deficits but that functional efficacy requires a more prolonged administration of drug. Future studies exploring the therapeutic efficacy window in more detail will be required to address these possibilities.
Effects of MW151 on glia morphological changes
To determine what effect, if any, MW151 had on microglia and astrocyte morphological activation, we measured IBA1, CD45, and GFAP immunohistochemistry. Using the Aperio ScanScope digital slide scanner and image software, we identified five brain regions of interest (ROI), which were outlined as illustrated in Figure 4A . Quantification of the digital slide was done using the positive pixel algorithm for the five ROIs. As shown by the heatmap in Figure 4B ,C,D, the largest increase in glial activation in the CHI mice compared to the sham mice was in the neocortex most proximal to the point of impact. The focus region of the neocortex, defined by an area that extended laterally from midline by 1.75 cm, showed a large increase in staining for all three markers (Figure 4E , F,G). In addition to the focus region, there were injuryinduced increases in staining in the entire neocortex (which included the focus regions), in the entorhinal cortex, and in the corpus callosum, but not in the hippocampus (see Table 2 ). Treatment with MW151 in the extended treatment paradigm (3 h, 6 h, and 1 to 7 days p.i.) reduced IBA1, CD45, and GFAP staining in the focus region of the cortex. There was little effect of MW151 treatment on glial staining in other areas of the brain. These IHC results cannot be directly compared to our Table 2 . Representative photomicrographs of IBA1 (E), CD45 (F), and GFAP (G) in the focus region of the neocortex show the robust glial morphological activation that occurs in response to the injury.
prior study [16] , where a different MW151 dosing paradigm and experimental protocols were used. However, the overall finding that repeat dosing with MW151 during the pathophysiology progression time window can alter glia IHC is consistent across studies.
Conclusions
Our goal is to develop safe and effective therapeutics that alter the pathological progression of TBI by reducing the potential for destructive glia inflammation/ neuron dysfunction cycles and their long-term cognitive effects. Consistent with this, MW151 has a documented disease-modifying efficacy in diverse animal models in which cognitive dysfunction is brought about by injuryor disease-induced overproduction of proinflammatory cytokines [9] [10] [11] [12] [13] [14] [15] [16] 26] . The results presented here extend the potential clinical utility of MW151 in CHI by documenting efficacy in a standard preclinical model of diffuse TBI. Exploration of dosing revealed that MW151 exerts its pharmacological mechanism of action at low concentrations even when administered up to 6 h following CHI. In addition, repeat administration of MW151 during the first 7 days after injury reduced the glial activation and cognitive impairment seen at 14 days after injury. Overall, the extended pharmacodynamics effect when MW151 intervention is performed during post-injury proinflammatory cytokine up-regulation is consistent with MW151 pharmacological mechanism of action and indicates the potential for efficacious use of MW151 administration up to several hours after injury. These results suggest that a therapeutic strategy targeting neuroinflammatory responses following TBI, such as with MW151, may have potential to be translated into improved clinical outcomes in human head injury. Competing interests DMW and LVE are principal investigators on project funding from the NIH and non-profit disease foundations that include the study of signal transduction pathways, drug target validation, or development of new molecular entities for treatment of CNS disorders. Northwestern University has filed patent applications covering future commercial use of MW151.
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